© Getty Images

Arrowhead highlights potential of RNAi in asthma at ERS 23

By Isabel Cameron

Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...

© GettyImages/Martin Barraud

4D Pharma sees positive data from early stage asthma trial

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, which has been NASDAQ listed since March this year, has announced positive topline results for the first part of its Phase I/II trial of an LBP strain for the treatment of asthma.